Artelo Biosciences, Inc. - נכסים נקיים למניה בודדת ARTL

A strategy focused on retaining top biochemists and geneticists provides Artelo Biosciences (ARTL) with a powerful intellectual resource. On the GURU.Markets platform, an analysis of the book value per share confirms the effectiveness of these investments, with the current figure standing at 10.82. Asset growth is driven by exclusive patents for the treatment of anorexia and the deep robotization of compound synthesis, which radically reduces costs at the preclinical stage.

Artelo Biosciences' development of innovative synthetic cannabinoid-based anticancer drugs and the patenting of therapies form the company's net asset base. By analyzing the absolute level of the book value per share, an investor can see the residual value of the business per security, allowing for a real-time assessment of the issuer's fundamental stability and the avoidance of value traps during declines in operating profitability.